Mack Gene — SEC Form 4 filings

SEC reporting owner CIK 1737979. 5 Form 4 filings on record with FilingPulse; latest filed 2026-03-26.

Transaction summary — filings shown

Covers all 5 filings on record, filed 2024-04-08 to 2026-03-26. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Gain Therapeutics, Inc. (GANX)CEO, President, Director51 leg · 14,400 sh · $14,5444

Form 4 filings — Mack Gene

FiledFormIssuerReported transactionsSource
2026-03-264Gain Therapeutics, Inc. (GANX)Grant/award (A): 200,000 (derivative) @ $0EDGAR
2025-03-214Gain Therapeutics, Inc. (GANX)Grant/award (A): 200,000 (derivative) @ $0EDGAR
2025-01-074Gain Therapeutics, Inc. (GANX)Grant/award (A): 271,325 (derivative) @ $0EDGAR
2024-08-124Gain Therapeutics, Inc. (GANX)Purchase (P): 14,400 @ $1.01EDGAR
2024-04-084Gain Therapeutics, Inc. (GANX)Grant/award (A): 200,000 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1737979 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →